Notable Health vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Mateo healthcare AI platform automating patient intake, insurance verification, care gap identification, and post-visit follow-up for health systems via EHR-connected AI agents.
About
Notable Health is a San Mateo-based healthcare AI company that provides health systems with an automation platform that handles repetitive clinical and administrative tasks — patient intake, pre-visit questionnaires, insurance verification, care gap identification, and post-visit follow-up — using AI agents deployed on health system infrastructure. Notable's platform connects to EHR systems to understand each patient's care context and proactively sends personalized communications and automated workflows at the right moments in the patient journey. By automating tasks that currently consume significant time from nurses, medical assistants, and front desk staff, Notable enables health systems to manage the same patient volume with fewer administrative staff or improve throughput without hiring. The company has documented millions of automated care actions with customers including Intermountain Health and Stanford Medicine. Founded in 2017, Notable raised over $100M from investors including F-Prime Capital, BOND, and Oak HC/FT, and competes with Olive AI (now closed) and Regard in the healthcare automation market.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.